Overview

Once-Daily Asenapine for Schizophrenia

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The investigators propose to explore: 1. the acceptance by patients of once versus twice daily dosing with asenapine, 2. the acceptance by staff of once versus twice daily dosing with asenapine, and 3. the changes in psychopathology associated with these two dosing strategies, in 30 patients with schizophrenia or schizoaffective disorder. The investigators hypothesize that patient and staff acceptance will be better with once daily dosing and that improvements in psychopathology will be similar across once daily and twice daily dosing
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Asenapine